КОДЗИМА Наоки (JP),РОМАН Дж. Ричард (US),МИЯТА Нориюки (JP),ТАКАХАСИ Тейсюке (JP),ТОМОИКЕ Хидеки (JP),ТАКЕДА Такуя (JP)
申请号：
RU2015110979
公开号：
RU2015110979A
申请日:
2013.08.30
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A medicament for treating a disease comprising, as a risk factor for cardiovascular events, at least hypertension or diabetes mellitus, which is characterized by a combination of an SGLT 2 inhibitor and an antihypertensive drug. The medicament according to claim 1, wherein the SGLT 2 inhibitor is a 1-thio-D-glucitol compound represented by the following general formula (I), a pharmaceutically acceptable salt thereof, or a hydrate of a compound or salt: [in formula (I) R is a hydrogen atom, a C 1-6 alkyl group, -OR or a halogen atom, R represents a hydrogen atom, a hydroxy group or -OR, R and R, which may be the same or different, each represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or -OR, R 2 represents (i ) a hydrogen atom, (ii) a halogen atom , (Iii) hydroxy, (iv) alkyl group, optionally substituted with a halogen atom, (v) -ORili (vi) -SR, where R is alkyl group, optionally substituted with a halogen atom.] 3. The medicament according to claim 2, wherein the 1-thio-D-glucitol compound is selected from the group consisting of: (1S) -1,5-anhydro-1- [3- (4-ethoxybenzyl) -6-methoxy-4- methylphenyl] -1-thio-D-glucitol, (1S) -1,5-anhydro-1- [4-chloro-3- (4-methylbenzyl) phenyl] -1-thio-D-glucitol, (1S) - 1,5-anhydro-1- [4-chloro-3- (4-methylthiobenzyl) phenyl] -1-thio-D-glucitol and (1S) -1,5-anhydro-1- [4-chloro-3- (4-ethylbenzyl) phenyl] -1-thio-D-glucitol. 4. The medicament according to claim 2, wherein the 1-thio-D-glucitol compound is (1S) -1,5-anhydro-1- [3- (4-ethoxybenzyl) -6-methoxy-4-methylphenyl] -1- thio-D-glucitol. 5. The drug according to claim 1, wherein the antihypertensive drug is a suppressor of the renin-angiotensin-aldosterone system. The medicament according to claim 5, wherein the renin-angiotensin-aldosterone suppressor1. Лекарственное средство для лечения заболевания, включающего в качестве фактора риска сердечно-сосудистых событий по меньшей мере гипертензию или сахарный диабет, которое характеризуется комбинацией ингибитора
